Pharma BD Deal Intelligence
A $42.9B combination that made Medtronic a medtech scale leader—Covidien's surgical devices became a durable growth franchise—but the market never rewarded it: Medtronic shares have trailed peers for a decade, and inherited hernia mesh litigation still lingers unresolved.
Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Medtronic acquired Covidien for $42.9 billion in cash and stock, creating one of the world's largest medical device companies. The deal combined Medtronic's cardiac and spinal surgery expertise with Covidien's surgical supplies and vascular products.
$40.0B Global Surgical Devices (2014)
Medtronic acquired Covidien for $42.9B in 2015, creating world's largest medtech. Brought surgical stapling, energy devices, monitoring, vascular. Also moved domicile to Ireland.
Gained #1 in surgical stapling and advanced energy. Complemented cardiac, spinal, diabetes franchises. Tax inversion saved ~$300M/yr.
Medtronic announces definitive agreement to acquire Covidien in the largest-ever medtech deal, offering $35.19 cash plus 0.956 Medtronic shares per Covidien share.
FTC grants clearance conditioned on divestiture of Covidien's drug-coated balloon catheter assets. EU and Canada also grant conditional approval.
Medtronic shareholders vote to approve the Covidien acquisition at a special meeting, clearing the final corporate governance hurdle before close.
Medtronic completes acquisition of Covidien for $42.9B in cash and stock, redomiciling to Ireland. Creates world's largest medtech company with ~$27B combined revenue.
Medtronic reports over $350M in cost synergies achieved by end of FY2016, on track toward $850M annual pre-tax synergy target by FY2018.
Medtronic achieves its $850M annual pre-tax cost synergy target by FY2018, integrating Covidien surgical portfolio and expanding minimally invasive surgery capabilities.
Deal validated as transformational for medtech. Medtronic revenue grew from $17B to $30B+, dominating cardiovascular, surgical, and neuromodulation markets. Integration synergies exceeded targets.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Medtronic plc / Covidien plc (this deal) | 2014 | $42.9B | 65 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Merck KGaA / Sigma-Aldrich Corporation | 2014 | $17.0B | 80 |
| Becton, Dickinson and Company / C.R. Bard Inc. | 2017 | $24.0B | 77 |
| Johnson & Johnson / Synthes Inc. | 2011 | $19.7B | 77 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Danaher Corporation / GE Life Sciences Biopharma Business (now Cytiva) | 2019 | $21.4B | 76 |